Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Papillary thyroid cancer (PTC) treatment is evolving beyond traditional methods.
• Individual patient risk and response are key factors in current therapeutic strategies.

Purpose of the Study:

• To review current and emerging treatment modalities for papillary thyroid cancer.
• To highlight the role of molecular techniques in risk stratification and treatment decisions.

Main Methods:

• Review of advancements in surgical and radioiodine therapies for local PTC.
• Analysis of directed therapies for metastatic PTC, including bisphosphonates, radiofrequency ablation, and radiotherapy.
• Evaluation of systemic therapies like tyrosine kinase inhibitors and future treatment directions.

Main Results:

• Personalized treatment strategies based on individual risk and response are standard.
• Molecular techniques are crucial for risk stratification and guiding therapy.
• Significant progress has been made in treating both local and metastatic PTC.
• Systemic therapies, particularly tyrosine kinase inhibitors, show promise but require individualized application.

Conclusions:

• Current PTC management emphasizes individualized, risk-adapted treatment approaches.
• Molecular diagnostics and targeted therapies are transforming PTC care.
• Future research will focus on overcoming radioiodine refractoriness and optimizing systemic treatments.